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Abstract
Methicillin-resistant Staphylococcus aureus (MRSA) continues to be a serious human pathogen, and particularly the spread of
community associated (CA)-MRSA strains such as USA300 is a concern, as these strains can cause severe infections in
otherwise healthy adults. Recently, we reported that a cyclodepsipeptide termed Solonamide B isolated from the marine
bacterium, Photobacterium halotolerans strongly reduces expression of RNAIII, the effector molecule of the agr quorum
sensing system. Here we show that Solonamide B interferes with the binding of S. aureus autoinducing peptides (AIPs) to
sensor histidine kinase, AgrC, of the agr two-component system. The hypervirulence of USA300 has been linked to increased
expression of central virulence factors like a-hemolysin and the phenol soluble modulins (PSMs). Importantly, in strain
USA300 Solonamide B dramatically reduced the activity of a-hemolysin and the transcription of psma encoding PSMs with
an 80% reduction in toxicity of supernatants towards human neutrophils and rabbit erythrocytes. To our knowledge this is
the first report of a compound produced naturally by a Gram-negative marine bacterium that interferes with agr and affects
both RNAIII and AgrA controlled virulence gene expression in S. aureus.
Citation: Nielsen A, Ma˚nsson M, Bojer MS, Gram L, Larsen TO, et al. (2014) Solonamide B Inhibits Quorum Sensing and Reduces Staphylococcus aureus Mediated
Killing of Human Neutrophils. PLoS ONE 9(1): e84992. doi:10.1371/journal.pone.0084992
Editor: Gunnar F. Kaufmann, The Scripps Research Institute and Sorrento Therapeutics, Inc., United States of America
Received March 28, 2013; Accepted November 22, 2013; Published January 8, 2014
Copyright:  2014 Nielsen et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by funding from the Programme Committee for Food, Health and Welfare under the Danish Strategic Research Council. The
funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: hi@sund.ku.dk
Introduction
Staphylococcus aureus is a serious human pathogen that causes a
variety of diseases, such as skin and soft tissue infections,
bacteremia, and toxic shock syndrome [1,2]. The organism is
well known for its ability to develop resistance to a wide range of
antibiotics and in consequence only few treatment options are now
available for the most resistant strains [3]. Resistance to methicillin
is particularly widespread, and nosocomial infections with
methicillin resistant S. aureus (MRSA) strains are one of the most
serious risk factors associated with hospitalization [4]. While the
hospital associated S. aureus strains are generally opportunistic
pathogens incapable of infecting healthy individuals [5] a more
aggressive group of strains have emerged since the early 1990s that
is both highly virulent and transmissible giving rise to infections in
the community, thus termed community associated, methicillin
resistant strains (CA-MRSA). The CA-MRSA strains belong to
several sequence types with USA300 (ST8) being the most
common in the US [6,7]. Importantly, these strains are able to
infect healthy individuals often giving rise to skin and soft tissue
infections that in some instances may turn out to be lethal [8,9].
Two of the most important virulence factors of CA-MRSA are
a-hemolysin [10] and the phenol soluble modulins, the PSMs [11].
a-hemolysin is a pore forming a-toxin that lyses immune cells such
as phagocytes, erythrocytes, and lymphocytes [12]. Also, a-
hemolysin is required for Staphylococcus aureus phagosomal escape
after internalization in a cystic fibrosis epithelial cell line [13].
PSMs are a class of secreted surfactant-like, amphipathic, alpha-
helical staphylococcal peptides and they are remarkable at
recruiting, activating and subsequently lysing human neutrophils.
There are four alpha-types and two beta-type PSMs. The alpha-
type PSMs are about 20–25 amino acids in length, and especially
PSMa3 is responsible for the lysis of human neutrophils. The beta-
type PSMs are longer, about 40–45 amino acids and lack cytolytic
activity [11,14]. Neutrophils constitute an essential part of the
innate immune system, as they hold strong phagocytotic activity
and are recruited to the site of infection in high numbers [15].
Thus, the production of PSMs is critical for the ability of S. aureus
to evade the host immune system and as such is determining for
the outcome of the infection [11].
The exceptionally high expression of toxins and exoenzymes by
CA-MRSA strains such as USA300 relies on the agr two-
component quorum sensing system encoded by agrACDB
[16,17]. With increasing cell density, autoinducing peptides (AIPs)
produced by agrB and agrD [18] accumulates in the extracellular
space and binds to the sensor histidine kinase, AgrC. Upon AIP
binding, AgrC activates the response regulator, AgrA that
stimulates transcription of a small regulatory RNA, RNAIII,
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Figure 1. Solonamide B does not influence RNAIII expression in the presence of a constitutively active AgrC. Cultures of RN10829 (P2-
agrA; P3-blaZ) containing either pagrC-I-WT (A, denoted WT) or pEG11 (B, denoted Const.) were grown to OD600 0.4–0.5 where 1/10 a volume of AIP-
containing supernatant and 5 mg/mL or 10 mg/mL Solonamide B (SolB) or DMSO was added. Controls not containing AIP were included to confirm
the inducible and constitutive nature of reporters in A and B, respectively. Samples were obtained at various time points after addition and were
analyzed for b-lactamase activity (P3 expression). A single representative experiment is depicted with bars representing the mean +/2 standard error
of the mean (SEM) from triplicate determinations of b-lactamase activity. Growth monitored for the WT strain confirms that the reduction in P3
expression is not due to growth impairment (C).
doi:10.1371/journal.pone.0084992.g001
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responsible for the expression of a-hemolysin and other toxins in
the late exponential growth phase [19,20]. AIPs consist of seven to
nine amino acids in which the central cysteine residue is covalently
linked to the terminal carboxylate, forming a thiolactone ring
[21,22]. Between strains, AIP structure varies giving rise to at least
four AIP classes where an AIP activates agr of strains only
belonging to the same class but represses agr of the other classes
[20]. In contrast to most toxins, expression of the PSMs is
controlled directly by AgrA that binds to the promoter region of
the psma and psmb operons respectively and activates transcription
[23].
In common to both community and hospital associated S. aureus
infections, resistance to antibiotics is an increasing problem and we
urgently need new approaches to prevent and treat S. aureus
infections caused by resistant strains [24–27]. Anti-virulence
compounds may offer an alternative to antibiotics, as they target
the expression or activity of virulence factors, rather than growth
or viability [28,29]. Examples of anti-virulence therapies include
neutralization of toxins using antibodies [30], prevention of
adhesion [31] or interference with virulence gene regulation
[32]. Advantages to such approaches may be that the host
microbiota is left unharmed and that there is likely to be less
selection of drug-resistance [33]. In a search for compounds that
reduce virulence gene expression in S. aureus we discovered that
Solonamide B which is produced by a marine Photobacterium
halotolerans, reduces expression of a-hemolysin and rnaIII and
increases expression of spa encoding protein A in both strain 8325-
4 and USA300 [34]. The purpose of the present study was to
determine the mode of action and the extent to which RNAIII and
AgrA controlled virulence factors were affected. We show here
that Solonamide B is likely to interact directly with the agr quorum
sensing system and that the activity of the compound is influencing
expression of both RNAIII and AgrA controlled toxins.
Materials and Methods
Bacterial Strains and Growth Conditions
S. aureus strains used in this study included: Strain NCTC 8325
(RN1), and 8325-4 [35] and FPR3757 USA300 a multidrug
resistant CA-MRSA isolate implicated in outbreaks of skin and soft
tissue infection [36]. For competition assays PC203 (S. aureus 8325-
4, spa::lacZ) [38] and RN6911 (S. aureus 8325-4 Dagr) [19] were also
employed. During the study we constructed a series of lux-reporter
strains. Plasmid from S. aureus strain RN9723 containing the
P3::luxABCDE construct (R. Novick) was phage transduced into S.
aureus strains with different agr group backgrounds (RN1 8325 agr
gr.I, RN6607 agr gr.II, MOZ53 agr gr.III (clinical isolate), RN4850
agr gr.IV, R. Novick) obtaining strain AN1: (RN1 8325 agr gr.I,
P3::luxABCDE, CMR), AN2: (RN6607 agr gr.II, P3::luxABCDE,
CMR), AN3: (MOZ53 agr gr.III,P3::luxABCDE, CMR) and AN4:
(RN4850 agr gr.IV, P3::luxABCDE, CMR. Strain RN10829/
pEG11 [40], a b-lactamase reporter strain substituting the native
Figure 2. Solonamide B competitively interferes with AIP binding to AgrC. Agar plates containing the spa-lacZ reporter strain PC203 were
supplied with 10 ml DMSO containing 0, 0.8, 4, 20, 100 and 500 mg Solonamide in DMSO and 20 ml of supernatant of overnight culture of 8325-4
(indicated as ‘‘WT’’) or RN6911, Dagr mutant cells (indicated as ‘‘Dagr’’) or TSB medium resulting in no (B) or the indicated concentrations of
solonamide B (A, C, D).
doi:10.1371/journal.pone.0084992.g002
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agr locus with a chromosomal integration of P2-agrA and P3-blaZ
and a plasmid from which a constitutive active variant of AgrC
(agrC-I-R238H) is expressed, was used to assess AgrC-dependent
effects of Solonamide B. Strain RN6911 [19] was used to generate
bacterial supernatant not containing auto-inducing peptide (AIP)
(strain 8325-4 was used to obtain supernatant containing AIP
gr.I.). Unless otherwise stated, bacteria were grown in Tryptone
Soya Broth (TSB), Oxoid, (1:10 volume/flask ratio), at 37uC with
shaking at 200 rpm.
Activity of Solonamide B in WT and Constitutive Active
AgrC reporter Strains
Plasmid pagrC-I-WT was generated by site-directed mutagenesis
(QuikChange Site-Directed Mutagenesis Kit, Agilent Technolo-
gies) using primers 59-aacaacgaaatgcgcaagttccgtcatgattatgtcaa-
tatcttaa-39 (AgrCHtoR_Fwd) and 59-ttaagatattgacataatcatgacg-
gaacttgcgcatttcgttgtt-39 (AgrCHtoR_Rev) containing the desired
nucleotide substitution (underlined) and plasmid pEG11 [40] as
template following the manufacturer’s instructions. Correct
reversion to AgrC-I-WT was confirmed by sequencing and by
displaying wild-type characteristics, i.e., an AIP-I-dependent
induction of b-lactamase activity in strain RN10829. Cultures of
reporter strains, containing either pagrC-I-WT or pEG11, were
diluted to OD600 0.05 in fresh TSB (without antibiotics) and grown
to OD600 0.4–0.5 (37uC, 225 rpm) followed by addition of 5 or
10 mg/mL Solonamide B (final concentration) or DMSO (solvent)
and 1/10 the volume of spent medium containing or free from
AIP-I. Bacterial samples were taken at indicated time points,
cooled instantly in an ice-water bath and frozen at 280uC. The
respective culture OD600 was recorded. b-lactamase activity of
samples was subsequently determined by the nitrocefin hydrolysis
method [21]. Briefly, 50 mL cell culture was added an equal
volume of 0.2 mM nitrocefin (Oxoid) in 0.1 M phosphate buffer
(pH 7.0) and measuring changes in OD486 over time in a
PowerWave XS microplate reader (BioTek) at 37uC. Activities
Figure 3. Assessment of competitive action of Solonamide B in P3-blaZ reporter strain. The inhibitory activity of 5 mg/mL Solonamide B
(SolB) on RNAIII expression controlled by wild type AgrC was assessed when challenged by increasing concentrations of AIP. b-lactamase activity was
determined with and without Solonamide B for three independent cultures (#1–#3) 30 minutes after addition of Solonamide B and induction by AIP.
Bars represent means +/2 SEM from triplicate activity determinations (A). Average inhibition obtained by Solonamide B at increasing AIP
concentrations. Bars represent the mean (+/2 SEM) reduction in b-lactamase activity observed from the three biological replicates (B). P-values
between AIP treatments were calculated by Student’s t-test (two-sided).
doi:10.1371/journal.pone.0084992.g003
Figure 4. Structures of AIP II and Solonamide B. AIP II (left), Solonamide B (right).
doi:10.1371/journal.pone.0084992.g004
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were calculated as arbitrary units based on respective conversion
velocities (Vmax, DOD486/time) normalized to the sample cell
densities.
Competition Assay
The reporter assay were made according to Nielsen et al. (2010)
[37] using the S. aureus 8325-4 derived spa::lacZ reporter strain [38]
or strain RN10829 carrying pagrC-I-WT. Sterile filtered superna-
tants from ON-cultures were made from S. aureus 8325-4 (wt) [35]
and S. aureus 8325-4 Dagr [19] grown in TSB. For AIP competition
experiments using the P3-blaZ reporter, 5 mg/mL Solonamide B
was challenged by addition of a fixed 1/5 volume of culture
supernatant, adjusted to contain 5%, 13%, or 20% AIP-I-
containing supernatant (final concentration), and the effect was
monitored in the AgrC-I-WT reporter strain. Solonamide B were
purified from cultures of the marine bacterium Photobacterium
halotolerans as described by Mannson et al. (2011) [34].
Figure 5. Solonamide B inhibits agr-group I, II and IV. The P3::lux reporter strains AN1 agr I, AN2 agr II, AN3 agrIII and agr IV AN4 were grown
with DMSO (control), Solonamide B 5 mg/mL, and Solonamide B 10 mg/mL. Luminescence was recorded after 2K hours of growth in the presence of
the compound. The luminescence is scored in % luminescence relative to the control (DMSO) set to 100% for each agr group individually and
standard deviations are calculated based on three replicates.
doi:10.1371/journal.pone.0084992.g005
Figure 6. Solonamide B specifically reduces a-hemolysin production. 1–256 fold dilutions of sterile filtered 24 hour culture supernatants
from USA300 cultures grown with DMSO, 5 mg/mL or 10 mg/mL of Solonamide B, were tested for its ability to lyse rabbit erythrocytes. 0.1% triton X
was used as a positive control. Hemolysis was scored in percentage relative to the DMSO control set to 100%. Data are a representative of at least two
independent, biological replicates.
doi:10.1371/journal.pone.0084992.g006
Figure 7. Solonamide B reduces psma and agrA expression.
Strains USA300 or 8325-4 were grown exponentially to OD600 = 0.4 with
either 5 mg/mL Solonamide B, DMSO or nothing added. RNA was
purified from samples collected at OD600 = 0.7 and 1.7, and analyzed by
Northern blotting. The membrane was probed with radioactive labeled
probes targeting agrA and psma.
doi:10.1371/journal.pone.0084992.g007
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Effect of Solonamide B on agr-group I, II, III and IV
Strain AN1, AN2, AN3 and AN4 were used for testing the effect
of Solonamide B on S. aureus with different agr backgrounds (agr gr.
I, II, III and IV). Cells were grown until OD600 = 0.4 and diluted
10 fold before distribution into a 96 well microtiter plate (100 mL
per well). Solonamide B dissolved in DMSO was added to the
microtiter well to a final concentration of 5 and 10 mg/ml. The
plate was incubated at 37uC in a microplate reader with shaking
every 10 minutes. Luminescence was recorded after 2K hour
incubation at OD600 = 0.3 in microtiter plates. For agr group III
luminescence was recorded every 20 minutes in the absence of
shaking.
Rabbit Erythrocyte Hemolysis Assay
1% suspension of rabbit erythrocytes were prepared by spinning
2 ml of rabbit blood at 3000 g for 10 min at 10uC, where after
supernatant was removed. Pellet was dissolved in 2 mL of PBS
containing 0.1% BSA (bovine serum albumin). Centrifugation and
washing was repeated until the supernatant was clear (approx 3
times). To prepare a 1% erythrocyte solution 100 mL erythrocytes
were dissolved in 10 ml PBS containing 0.1% BSA. To prepare
culture supernatants S. aureus USA300 (FPR3757) cultures were
spun at 5000 g for 10 minutes to pellet the bacteria. The
supernatant was transferred to new eppendorf tubes, and dilution
rows (2-fold dilutions) were made in TSB. 100 mL of 1%
erythrocytes suspension was added to 100 ml culture supernatant
in a 96 well microtiter plate and incubated for 30 minutes at 37uC
and 30 minutes at 4uC. 0.2% Triton X in TSB (final concentration
of 0.1%) was used as a positive control, and TSB was used as a
negative control. The microtiter plate was spun at 2000 rpm for 2
minutes, supernatant was transferred carefully to a new plate and
read at OD450.
Transcriptional Analysis of agrA and psma by Northern
Blot
Northern blot analysis was performed as described previously
[39]. The strains used were S. aureus 8325-4 and FPR 3757
USA300, and were grown in Erlenmeyer flasks, shaking at
185 rpm. Growth was monitored by measuring optical density at
OD600. Start inoculum was OD600 = 0.03. Solonamide B was
added at OD600 = 0.4. Samples for RNA purification were taken
at OD600 = 0.7 and 1.7. Probes targeting AgrA and PSMa
transcripts were amplified by PCR using the primers AgrA fwd:
59 ctgataatccttatgaggtgc 39, AgrA rev: 59 cgatgcatagcagtgttc 39,
PSMa rev: 59 tatcaaaagcttaatcgaacaattc 39 and PSMa fwd:59
ccccttcaaataagatgttcatatc 39 (from TAG Copenhagen A/S, Den-
mark) resulting in probe lengths of 584 bp (AgrA) and 176 bp
(PSMa) respectively.
S. aureus lysis of Human Neutrophils
Sterile filtered supernatants from 7 h and 22,5 h S. aureus LAC/
FPR3757 (USA300) cultures grown in 10 mL TSB media/
100 mL Erlenmeyer flasks, with a start inoculum OD600 = 0.02
and either DMSO (control) or Solonamide B (5 and 10 mg/mL)
added to the cultures were tested for their capacity to lyse human
neutrophils. Bacterial supernatants were collected from three
independent experiments on different days, and stored at 220uC
until used. Lysis of human neutrophils was determined using
Cytotoxicity Detection Kitplus (LDH) from Roche (measuring
lactate dehydrogenase release), manufacturer’s protocol was
followed. Supernatants diluted 3- and 9-fold and undiluted
supernatants were tested. Neutrophil lysis was determined
spectrophotometrically at A490 nm-A630 nm after 1 h incubation
at 37uC of 100 mL neutrophils (50,000 cells per well)+50 mL
supernatant/TSB in microtiter wells. Data is a representative of 3
biological replicates, and each supernatant was tested at least in
replicate wells. Neutrophils were isolated by Ficoll-hypaque
purification from fresh heparinized human blood from healthy
volunteers according to the regulations of National Committee on
Health Research Ethics in Denmark. Using blood for assessment
of effects of microorganisms or microbial components does not
require approval from the committee (law no 593 of June 14,
2011). Blood was mixed with equal volume of dextran (3%)/saline
(0.9%), and incubated at room temp. for 20 min. The upper
leukocyte rich layer was saved and centrifuged 10 min at 5uC at
250 g. Pellet was resuspended in 0.9% NaCl (equal to start
volume). Ficoll-hypaque was gently layered under the cell
suspension and centrifuged for 40 min. The red blood cells
present in the pellet were lysed and cleared by washing with ice
cold 0.2% NaCl for 30 sec. followed by adding 1.6% NaCl and
centrifuging for 6 min at 250 g until colorless pellet was obtained
and neutrophils were resuspended in ice-cold PBS/glucose
(10 mM).
Results
Solonamide B Interferes with agr Activation
From the marine bacterium Photobacterium halotolerans we recently
identified a cyclodepsipeptide, Solonamide B that interferes with
virulence gene expression in S. aureus without inhibiting growth.
The reduction in hla and RNAIII expression and increase in spa
transcription provided circumstantial evidence that Solonamide B
may interfere with agr activation [34]. To address this issue we
examined the effect of the compound on RNAIII expression in a
strain carrying an AgrC variant with a substitution at R238H in
the histidine kinase domain that allows AgrC to be active
independently of AIPs [40]. If, indeed, solonamide B acts through
AgrC we predicted that RNAIII expression in cells carrying the
constitutive variant would be unaffected by the compound in
comparison to cells expressing the wild type AgrC. At solonamide
B concentrations not affecting growth RNAIII (fig. 1C) promoter
(P3) activity was monitored in strain RN10829 carrying a
chromosomal P3::blaZ reporter fusion in addition to plasmids
pagrC-I-WT or pEG11 expressing wild type or constitutive AgrC,
respectively. Since this strain does not produce AIP, agr was
induced by addition of 1/10 a volume of spent medium obtained
from wild type 8325-4 cells in stationary growth phase. We found
that in the presence of the constitutive AgrC (fig. 1B), Solonamide
B did not affect the P3 promoter activity at concentrations that
reduced RNAIII expression significatly in cells expressing wild
type AgrC (fig. 1 A). Thus, our results show that the effect of
Solonamide B on virulence gene expression is mediated via
interactions with AgrC. Furthermore, we noted a tendency
towards a dose-dependency on Solonamide B (fig. 1A) suggesting
competitive activity.
To address if Solonamide B interferes competitively with AIP
binding to the AgrC receptor we added varying amounts of
Solonamide B to wells in our reporter assay also containing fixed
amounts of culture supernatant from either stationary phase 8325-
4 cells or from agr mutant cells (fig. 2). Here, we observed that a
fixed concentration of solonamide B induced spa expression of the
incorporated reporter strains both in the presence of spent
medium of wild type and agr mutant cells thus indicating inhibition
of agr activity (fig. 2A). When reducing the amount of solonamide
B only the lowest concentration (corresponding to 0.05 mM in the
well) was unable to induce spa expression in competition with spent
medium of wild type cells (fig. 2C). However, at the same
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solonamide B concentration we did see expression of spa when
competed with supernatant obtained from agr mutant cells lacking
AIP production thus confirming that solonamide B competes with
AIP for AgrC binding (fig. 2D). A more quantitative measure of
the competition was obtained with the P3-blaZ reporter strain
exposed to a fixed concentration of Solonamide B (5 mg/mL) and
dilutions of the spent supernatant from stationary phase, wild type
cells. The results (fig. 3) show that 50% inhibition was reached
Figure 8. Solonamide B protects against S. aureusmediated neutrophil lysis. Sterile filtered supernatants of S. aureus USA300 (S.a.) cultures
grown for 7 hours or overnight (ON) with either Solonamide B at 5 mg/mL or 10 mg/mL or DMSO (control) were added to isolated human neutrophils.
The control supernatant where only DMSO was added was tested in 1-fold, 3-fold and 9-fold dilutions (A). Undiluted (1:1) supernatants from
Solonamide B (SolB) treated cultures are shown together with the control in (B) and 3-fold dilutions (1:3) are shown in (C). Lysis was monitored by
lactate dehydrogenase (LDH) release. Data represents 3 independent experiments, using the average of triplicate wells from each experiment.
Asteriks indicate SolB treated cultures resulting in lysis statistically significant from the corresponding control. *, p,0.05, **, p,0.01; ***, p,0.001.
doi:10.1371/journal.pone.0084992.g008
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when challenged by 5% supernatant, which is comparable to the
reduction in P3 activity observed for 10 mg/mL Solonamide B in
10% supernatant (fig. 1A). By increasing the AIP activator
concentration a gradual and significant reduction in Solonamide
B inhibition is evident, clearly showing the AIP-competitive AgrC-
inhibitory activity of Solonamide B (fig. 3).
Solonamide B Inhibits more than One agr Specificity
Group
Interestingly, the cyclic structure of Solonamide B resembles the
backbone of the native AIPs (fig. 4) that are thiolactones
containing seven to nine amino acid residues in which the thiol
of the central cysteine is linked to the alpha-carboxyl of the C-
terminal amino acid residue [34,41]. As the thiolactone ring of
AIPs is involved in agr repression while the peptide tails are linked
to activation [42] we examined if Solonamide B inhibits more than
one AIP specificity group. To this end we grew S. aureus P3::lux
reporter strains belonging to the different agr specificity groups in
the presence or absence of Solonamide B and measured
luminescence after 2K hr incubation at OD600 = 0.3 in the
microtiter plate. As observed in fig. 5 luminescence expressed by
the P3 promoter for agr group I and II, was reduced 5 fold when 5
and 10 mg/mL Solonamide B was added compared to the control
wells containing DMSO. The strain carrying the agr specificity
group IV showed a 2–3 fold decrease in P3::lux expression when
treated with Solonamide B, and the luminescence declined with
the higher concentration of Solonamide B. The expression pattern
remained unchanged after 3K, 4K, 5K h and ON incubation
(data not shown). For agr group III an effect was seen already after
20 minutes resulting in 25% and 35% reduction with 5 and
10 mg/mL Solonamide B, respectively compared to the DMSO
control with the effect declining over time (data not shown).
Altogether these results show that Solonamide B reduces agr
expression in all the specificity groups, as measured by P3 activity,
with the least effect towards agr group III.
Solonamide B Interferes with Hemolysin Production
Hemolysis is one of the major virulence factors in S. aureus
pathogenesis [43]. As we had previously seen that hla transcription
was strongly reduced by Solonamide B [34] we sought to confirm
that hemolytic activity was also affected. We chose to use rabbit
erythrocytes for the hemolysis assay as they are known to be
particularly susceptible to a-hemolysin [44,45]. When testing
supernatants from S. aureus cultures grown with and without
Solonamide B on rabbit erythrocytes we observed that Solona-
mide B reduced production of hemolysin(s) in S. aureus strain
USA300 (fig. 6). In contrast, the solvent DMSO did not inhibit
hemolysin production (fig. 6). When comparing the lytic activities,
50% hemolysis of rabbit erythrocytes was observed with a 64 fold
dilution of the USA300 culture supernatants whereas it was seen
for an eight fold dilution of supernatant from USA300 cells treated
with 5 mg/mL solonamide B and at a three fold dilution for those
treated with 10 mg/mL solonamide B. Thus, hemolysin activity is
reduced in the presence of Solonamide B.
Solonamide B Reduces psma Transcription
The PSM phenol soluble modulins are implicated as key
virulence factors of CA-MRSA such as USA300 and in contrast to
most S. aureus virulence genes, their expression is controlled
directly by the AgrA response regulator [23]. To determine the
potential of Solonamide B as an anti-virulence compound
targeting CA-MRSA strains, we examined the effect of Solona-
mide B on the transcription of the psma operon encoding the
alpha-type PSMs. Importantly, when bacterial cells were cultured
in the presence of Solonamide B there was a dramatic effect on
psma expression as the presence of the compound essentially
abolished expression in both strain 8325-4 and USA300 (fig. 7).
To assess if this effect is correlated with agrA expression we probed
the agr P2 transcript with a probe covering agrA and found it to be
significantly decreased in both strains but most so in USA300.
Thus, the reduced expression of psma is likely caused by reduced
expression of agrA.
Solonamide B Reduces PSM Expression and Neutrophil
Killing
Neutrophils are a part of the innate immune system, and as the
first leukocytes that infiltrate affected tissues they are one of the
primary defenses against Staphylococcal infection [46,47]. S. aureus
produces PSMs of which the alpha type PSM is the most
important for neutrophil lysis, with PSMa3 having the most
pronounced effect [11,23]. Since our transcriptional analysis
revealed that Solonamide B dramatically reduces expression of
psma we examined if it may be protective of S. aureus mediated
neutrophil killing. To this end we monitored toxicity of sterile
filtered CA-MRSA USA300 supernatant grown with and without
Solonamide B on human neutrophils (Fig. 8). As above, growth
rate and maximum cell density of S. aureus was identical with and
without Solonamide B (data not shown). Importantly, we found
that Solonamide B offered a significant reduction in the toxicity of
7 h and ON culture supernatants of USA300. Thus, the
transcriptional effects on both hla and psma are translated into
reduced toxin production; though other factors than PSM may
contribute to neutrophil lysis as well.
During these studies we did not observe lysis of human
neutrophils or of bovine erythrocytes at any of the tested
concentrations (up to 20 mg/mL) of Solonamide B thus indicating
that Solonamide B displays low toxicity (data not shown).
Discussion
In times where antibiotic resistance is evolving towards most
known antibiotics and the development of new antibiotics is
lacking far behind we are searching for alternatives to treat serious
infectious diseases. One approach that has received considerable
interest is anti-virulence therapy where the virulence of the
pathogen is targeted rather than viability. In this context we
recently isolated a compound from the marine bacterium
Photobacterium halotolerans that interfered with virulence gene
expression in S. aureus. The compound termed Solonamide B
inversely affected transcription of hla and spa indicating that it
interferes with activation of the agr quorum sensing system [34].
We have addressed this hypothesis further by investigating the
effect of Solonamide B in mutant cells expressing a variant of the
AgrC sensor histidine kinase that is active irrespectively of the
presence of the AIP auto-inducing peptides [14]. In this strain
background the expression of rnaIII was unaffected by the
compound strongly indicating that Solonamide B interferes with
virulence gene expression by compromising AgrC activation and
thus, quorum sensing.
A characteristic property of the S. aureus agr system is the
presence of at least four agr subclasses, in which an AIP from one
class induces agr in strains of its own class but represses agr of the
other subclasses [18,48]. Structural studies of the AIPs have
revealed that the macrocyclic ring of the AIPs is responsible for
inhibition of agr, while the peptide tail is required for agr-activation
[18,49]. It has been shown that truncated versions of group II AIPs
inhibit all four agr groups, and that AIP analogs with oxygen or
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nitrogen in place of sulfur in the ring structure (i.e., the lactone or
lactam vs. the thiolactone) are potent intergroup inhibitors even
though they neither activate nor inhibit their cognate receptors
[50]. Like the AIPs, Solonamide B is a non-ribosomal peptide with
a 16-membered core macrocyclic ring. Both compounds are
depsipeptides, however whereas Solonamide B is a lactone, AIP is
a thiolactone. Thus, the overall size of the cyclic moiety is quite
similar with the peptide tail of the AIPs being replaced by a
hydroxy-fatty acid in Solonamide B [34]. When examining
Solonamide B we found that it interfered well with agr activation
in three of the four known classes of agr and had a minor effect on
agr group III. The ability to interfere with agr of several subclasses
correlates with the cyclic structure of the compound, and the
differences observed may be related to the individual AIP
structures or the temporal RNAIII induction pattern [51].
S. aureus is a versatile pathogen and in recent years the CA-
MRSA strains such as USA300 have caused particular concern as
they are known for their ability to spread and cause severe
infections in otherwise healthy people [9,36,52]. Among the
virulence factors contributing to the success of these strains is
efficient agr activation including high expression levels of a-
hemolysin as well as the production of the phenol soluble modulins
(PSMs) [14]. Neutrophils are one of the primary host defenses
against S. aureus infections and therefore, neutrophil lysis is
important for the virulence of these strains [11]. Importantly we
found that Solonamide B dramatically reduces transcription of
psma in CA-MRSA strain USA300 as well as the overall toxicity of
the culture supernatants when tested against human neutrophils.
In contrast to many other virulence factors in S. aureus the
expression of PSMs is directly controlled by the response regulator,
AgrA [23] and also the transcription of agrA was significantly
reduced by the Solonamide B. Thus our data show that
Solonamide B not only interferes with production of virulence
factors belonging to the RNAIII regulon but also expression of
agrA and the AgrA controlled PSMs.
When comparing the ability of Solonamide B to compete with
AIP for binding we found that 5 mg/mL solonamide correspond-
ing to 8.5 mM provide 50% inhibition in spent medium of wild
type cells containing approximately 0.25 mM AIP (estimated as
5% of 5 mM, Alexander Horswill, personal communication).
Thus, although we with the examined compound see a significant
reduction in S. aureus virulence, structural optimizations may
increase the inhibitory potential even further. In conclusion we
show that Solonamide B interferes with agr activation by binding
to the AgrC sensor histidine kinase and thereby preventing
interactions between AgrC and the AIPs. As an anti-virulence
compound Solonamide B demonstrates potential due to its low
toxicity, its inhibitory effect towards the known classes of agr and its
ability to reduce expression of the PSMs involved in the severe
CA-MRSA infections.
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